New Antibody Targets Severe Asthma

Trial Objective

The purpose of this study is to see if a medication called tezepelumab is effective in treating severe asthma and if it causes side effects.

New Antibody Targets Severe Asthma

Tezepelumab is a man-made antibody, a protein produced by specific cells in the immune system that react to a substance that the body sees as foreign, such as bacteria or viruses. Tezapelumab reacts with a substance called thymic stromal lymphopoietin (TSLP), which is known to play a role in causing asthma. The Food and Drug Administration (FDA) has not approved tezepelumab for the treatment of asthma. Its use in this study is considered investigational.


This trial is active and currently recruiting.

How to Participate

For more information, contact Allen Stevens at 303.398.1443 or complete the form below.

Who Can Participate

People who have the following may be eligible to participate: (1) poorly controlled asthma for at least 12 months, (2) a physician-prescribed asthma controller with medium- or high-dose inhaled corticosteroid (ICS) such as Flovent®, (3) an additional controller inhaler, including combination inhalers such as Symbicort® or Advair®.

Estimated Time Commitment

19 visits over 69-71 weeks

Trial Location

National Jewish Main Campus, Denver, CO



Trial Sponsors

AstraZeneca AB




Any Gender

Principal Investigators

Request More Information